Coherus Acquires Rights From Klinge Biopharma for Eylea Biosimilar Candidate
Coherus BioSciences has inked a licensing deal with Klinge Biopharma for the exclusive U.S. commercial rights to FYB203, Klinge’s investigational biosimilar of Regeneron’s blockbuster drug Eylea (aflibercept).
FYB203 is currently in a phase 3 study to evaluate its safety and efficacy compared with Eylea in patients with wet age-related macular degeneration.
Under the deal, Klinge will receive an upfront payment of approximately $32.5 million. The transaction is expected to be completed in the first quarter of this year.
Coherus plans on filing a biologics license application to the FDA for the biosimilar candidate later this year and aims to launch the product in 2025.